Drug Profile
Research programme: dual tumour necrosis factor/matrix metalloproteinase inhibitors - Roche
Alternative Names: Dual TNF/MMP inhibitors research programme - Roche; Dual tumour necrosis factor/matrix metalloproteinase inhibitors research programme - Roche; Research programme: dual TNF/MMP inhibitors - RocheLatest Information Update: 12 Apr 2007
Price :
$50
*
At a glance
- Originator Roche Palo Alto LLC
- Class
- Mechanism of Action Matrix metalloproteinase inhibitors; Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 12 Apr 2007 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)
- 07 Sep 2004 Preclinical trials in Rheumatoid arthritis in USA (PO)